ABBV - AbbVie Inc.
The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.
Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
It is certainly a good Dividend King to buy in September.
AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
These three stocks meet multiple criteria for long-term dividend investing success.
AbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company's established SKYRIZI and RINVOQ franchises.
R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics. A featured SkinMedica ® R&D panel on exosomes will introduce the FACTS Principles and examine the scientific questions shaping responsible innovation in this rapidly evolving category.
Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.
The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.
Two portfolios generating identical dividend income can leave one investor thousands of dollars richer than the other, and the difference has nothing to do with yield. The culprit is hiding inside your 1099-DIV.
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put the right stocks inside it. Five blue chips with records stretching back decades make a compelling case for why account placement matters as much as stock selection.
Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.
NorthRock Partners LLC increased its position in shares of AbbVie Inc. (NYSE: ABBV) by 3.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,702 shares of the company's stock after purchasing an additional 1,946 shares during the period. NorthRock Partners
SVB Wealth LLC trimmed its position in AbbVie Inc. (NYSE: ABBV) by 4.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,432 shares of the company's stock after selling 2,857 shares during the quarter. AbbVie comprises 0.8% of SVB Wealth LLC's
Summit Financial Strategies Inc. cut its stake in AbbVie Inc. (NYSE: ABBV) by 34.4% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,278 shares of the company's stock after selling 4,873 shares during the period. Summit Financial Strategies Inc.'s holdings in AbbVie were worth
NewEdge Advisors LLC cut its position in shares of AbbVie Inc. (NYSE: ABBV) by 30.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 439,164 shares of the company's stock after selling 192,976 shares during the quarter. NewEdge Advisors